scispace - formally typeset
F

Francesca Romana Ponziani

Researcher at Agostino Gemelli University Polyclinic

Publications -  170
Citations -  3929

Francesca Romana Ponziani is an academic researcher from Agostino Gemelli University Polyclinic. The author has contributed to research in topics: Medicine & Internal medicine. The author has an hindex of 28, co-authored 113 publications receiving 2617 citations. Previous affiliations of Francesca Romana Ponziani include Catholic University of the Sacred Heart & Sapienza University of Rome.

Papers
More filters
Journal ArticleDOI

Thrombotic risk factors in patients with liver cirrhosis: Correlation with MELD scoring system and portal vein thrombosis development

TL;DR: Lower concentrations of natural coagulation inhibitors are frequently detected in patients with liver cirrhosis and a reduced portal flow velocity seems to be the most important predictive variable for PVT development in patientsWith cirrhotic patients.
Journal ArticleDOI

Portal vein thrombosis: Insight into physiopathology, diagnosis, and treatment

TL;DR: In this article, the authors analyzed the physiopathological mechanisms of portal vein thrombosis, together with the hemodynamic and functional alterations related to this condition, and described the principal factors most frequently involved in PVT development and the recent knowledge concerning diagnostic and therapeutic procedures.
Journal ArticleDOI

Gut Microbiota during Dietary Restrictions: New Insights in Non-Communicable Diseases

TL;DR: An overview of animal and human studies focusing on gut microbiota variations during different types of dietary restriction is provided in order to highlight the close relationship between gut microbiota balance and the host’s health benefits induced by these nutritional regimens.
Journal ArticleDOI

Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation

TL;DR: An increase in Bifidobacterium, Faecalibacterium prausnitzii and Lactobacillus abundance after rifaximin treatment is demonstrated, probably consequent to the induction of bacterial resistance, with no major change in the overall gut microbiota composition.